FDA spends $1.2M on VR-enabled hub to spur development of at-home care devices

The Food and Drug Administration (FDA) has launched a new initiative through its device centre aimed at promoting the development of at-home medical devices with a specific focus on advancing health equity in home care. The agency has allocated $1.2 million to kickstart this partnership, according to a spokesperson for the FDA.

This initiative, titled "Lessons from the Home as a Health Care Hub," seeks to provide valuable insights that could shape future regulations and technologies utilised in hospital-at-home programs. By fostering collaboration among medical device developers, policymakers, and healthcare providers, the FDA aims to facilitate the development and understanding of at-home medical technologies.

In a press release attributed to Dr. Jeff Shuren, Director of the Center for Devices and Radiological Health (CDRH), the FDA highlights the current challenges faced by at-home care options in effectively navigating the home environment. The agency emphasises the importance of considering the structural and critical elements of the home when transferring care to this setting.

To aid in this endeavour, the FDA has commissioned Dallas-based architectural firm HKS Inc. to construct a virtual reality model of a typical home. This VR model is intended to provide developers and policymakers with a better understanding of the structural elements of a home that may impact the use of at-home medical devices. Initially, the focus of these models will be on rural and low-income populations.

The FDA's interest in ensuring the safety of at-home medical devices dates back to 2010, when the agency released a white paper on the topic. However, the recent surge in the use of at-home medical devices and software, particularly in the context of providing acute-level hospital care at home, has prompted renewed attention from the FDA.

Recognizing the evolving landscape of healthcare delivery, including the growing utilisation of hospital-at-home programs, the FDA seeks to enhance its understanding of these technologies to better regulate them. This initiative builds upon previous efforts by the FDA, such as requests for public comment on at-home medical devices and engagement with the Patient Engagement Advisory Committee.

In May 2023, the FDA acknowledged that its authority to regulate medical devices alone may not be sufficient to ensure the safety of at-home medical devices. The agency highlighted an increasing number of adverse reports related to the use of such devices and emphasised the need for additional measures to safeguard patient well-being.

Click here to read the original news story.